Request Your Free White Paper Now:

"Vaccine Development Challenges in Facing Influenza and COVID-19"

Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead.

The development of safe and effective vaccines for influenza and COVID-19 is an intricate process that necessitates extensive research, rigorous clinical trials, and regulatory approval. To address the evolving nature of these viruses, vaccine developers must continuously adapt and update their products to target new strains and variants that emerge over time.

While the RNA genetic materials are in both the influenza (types A, B, and rarely C) and SARS-CoV-2 virus, there are also notable differences in their biological characteristics. Such as their genetic makeup, structure, replication mechanism, and interaction with the immune system, as well as differences in recommendations for vaccination schedules.

Learn more in this white paper by Dr. Lisa Kierstead (Executive Director, Vaccine Sciences Lab, PPD, part of Thermo Fisher Scientific), where she delves further into the challenges encountered by the vaccine industry and emphasizes the need for continuous and comprehensive research to monitor the effectiveness of existing vaccines against new variants and to inform future vaccine development strategies.

Offered Free by: PPD
See All Resources from: PPD